Sanofi prevails over Boehringer Ingelheim in legal battle over Zantac liabilities
Fierce Pharma
JUNE 20, 2023
When Sanofi made an asset swap with Boehringer Ingelheim in 2016, the French company acquired BI’s healthcare business, which included heartburn medicine Zantac. | In an asset swap with Boehringer in 2016, Sanofi gained U.S. marketing rights to the treatment.
Let's personalize your content